Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.36 |
| ▸ | CASP8 | Q14790 | 4/20 | 0.36 |
| ▸ | CASP1 | P29466 | 3/20 | 0.36 |
| ▸ | CASP7 | P55210 | 3/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.35 |
| ▸ | BACE1 | P56817 | 3/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11037525 | 0.91 | CTSC (0.39) | ENPEP | |
| SCHEMBL29375970 | 0.87 | MME (0.46) | ENPEPBACE1BACE2 | |
| SCHEMBL29375430 | 0.87 | MME (0.46) | ENPEPBACE1BACE2 | |
| SCHEMBL2183916 | 0.82 | MME (0.37) | ENPEP | |
| SCHEMBL676220 | 0.82 | BACE1 (0.48) | CASP3CASP7BACE1BACE2 | |
| SCHEMBL2672789 | 0.82 | OPRD1 (0.42) | CASP1ENPEPBACE1CTSDBACE2 | |
| SCHEMBL2190022 | 0.81 | CTSC (0.39) | ENPEPBACE1CTSD | |
| SCHEMBL30906339 | 0.81 | MME (0.41) | BACE1CTSD | |
| SCHEMBL2181799 | 0.80 | CTSC (0.34) | — | |
| SCHEMBL30165201 | 0.79 | ENPEP (0.43) | CASP3CASP8CASP1CASP7ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | CASP3 3181/4885CASP8 4013/4885CASP1 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.